Federal Circuit Holds Adequate Notice of PTAB's Claim Construction Provided Through Oral Hearing
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
TQ Delta LLC v. Dish Network LLC
Before: Newman, Linn, and Wallach. Appeal from the Patent Trial and Appeal Board.
Summary: The rights of parties in an IPR are not violated when the PTAB provides adequate notice of the PTAB’s understanding of the claim construction during the oral hearing.
Dish Network ("Dish") petitioned for inter partes review of a patent owned by TQ Delta, LLC ("TQ Delta") which describes a method to manage the power of a transceiver in sleep mode and to wake up the transceiver from sleep mode. The PTAB found the claims were obvious. TQ Delta appealed, arguing in part that the PTAB violated its rights by changing course to a new claim construction in the Final Written Decision.
The Federal Circuit found that the PTAB did not violate TQ Delta's rights. The Federal Circuit determined that the PTAB did not “change course” because the PTAB did not construe the term in its Decision to Institute. Additionally, the Federal Circuit found that TQ Delta had notice of the PTAB's interpretation of the term from the PTAB's questions during the Oral Hearing, where it was given the opportunity to respond. The Federal Circuit also affirmed the PTAB's claim construction, finding support for the PTAB’s construction in the surrounding claims and specification. The Federal Circuit further affirmed the PTAB's finding of obviousness.
Editor: Paul Stewart
Written by: Lindsay Laddaran & Kendall Loebbaka
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…